{
    "clinical_study": {
        "@rank": "84099", 
        "arm_group": {
            "arm_group_label": "DESyne Novolimus Eluting CSS", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the long-term safety and performance of the DESolve Novolimus Eluting\n      Bioresorbable Coronary Scaffold System"
        }, 
        "brief_title": "DESolve Post-Approval Study", 
        "completion_date": {
            "#text": "November 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "DESolve is not currently approved for sale in the United States."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be at least 18 years of age\n\n          -  Patient is able to verbally confirm understanding of risks, benefits and treatment\n             alternatives of receiving the DESolve NE BCSS and he/she provides written informed\n             consent, as approved by the appropriate Ethics Committee of the respective clinical\n             site, prior to any clinical study related procedure\n\n          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,\n             silent ischemia, positive functional study or electrocardiogram (ECG) changes\n             consistent with ischemia)\n\n          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)\n             surgery\n\n          -  Patient must agree to undergo all clinical study required follow-up visits\n\n          -  Patient must agree not to participate in any other clinical study for a period of two\n             years following the index procedure\n\n        Angiographic Inclusion Criteria - Target Lesion/Vessel Target lesion must be located in a\n        native coronary artery with a nominal vessel diameter of between 2.75 and 3.5 mm assessed\n        by visual estimation or QCA\n\n          -  Target lesion must measure \u2264 24 mm in length\n\n          -  Target lesion must be in a major artery or branch with a visually estimated stenosis\n             of \u2265 50% and < 90% with a TIMI flow of \u2265 1\n\n          -  Percutaneous intervention of lesions in the target vessel if:\n\n          -  Not part of a clinical investigation\n\n          -  \u2265 6 months prior to the study index procedure\n\n          -  \u2265 9 months after the study index procedure (planned)\n\n          -  Previous intervention was distal to and > 10 mm from the target lesion\n\n        Exclusion Criteria:\n\n          -  Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours\n             preceding the index procedure and CK and CK-MB have not returned within normal limits\n             at the time of procedure\n\n          -  Patient is currently experiencing clinical symptoms consistent with AMI\n\n          -  Patient requires the use of any rotablator intervention during the index procedure\n\n          -  Patient has current unstable arrhythmias\n\n          -  Patient has a known left ventricular ejection fraction (LVEF) < 30%\n\n          -  Patient has received a heart transplant or any other organ transplant or is on a\n             waiting list for any organ transplant\n\n          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30\n             days prior to or after the procedure\n\n          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or\n             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus)\n\n          -  Patient is receiving chronic anticoagulation therapy (e.g., heparin, Coumadin) that\n             cannot be stopped and restarted according to local hospital standard procedures\n\n          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and\n             bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast\n             sensitivity that cannot be adequately pre-medicated\n\n          -  Elective surgery is planned within the first 6 months after the procedure that will\n             require discontinuing either aspirin or clopidogrel\n\n          -  Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of <\n             3,000 cells/mm3, or documented or suspected liver disease\n\n          -  Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5\n             mg/dL, or patient on dialysis)\n\n          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood\n             transfusions\n\n          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological\n             attack (TIA) within the past six months\n\n          -  Patient has had a significant GI or urinary bleed within the past six months\n\n          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath\n             insertion\n\n          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known\n             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause\n             non-compliance with the clinical study plan, confound the data interpretation or is\n             associated with a limited life expectancy (i.e., less than one year)\n\n          -  Patient is already participating in another clinical study\n\n          -  Women of childbearing potential who have not undergone surgical sterilization or are\n             not post-menopausal (defined as amenorrheic for at least one year) as well as women\n             who are pregnant or nursing\n\n          -  Patient is unable to give their consent, is legally incompetent, or is\n             institutionalized by virtue of an order issued by the courts or other authority\n\n        Angiographic Exclusion Criteria - Target Lesion/Vessel\n\n          -  Target lesion(s) meets any of the following criteria:\n\n          -  Aorto-ostial location\n\n          -  Left main location\n\n          -  Located within 5 mm of the origin of the LAD or LCX\n\n          -  Located within an arterial or saphenous vein graft or distal to a diseased arterial\n             or saphenous vein graft\n\n          -  Lesion involving a side branch >2mm in diameter or bifurcation\n\n          -  Previous placement of a scaffold proximal to or within 10 mm of the target lesion\n\n          -  Total occlusion (TIMI flow 0), or sub-total occlusion (TIMI flow 1)\n\n          -  Excessive tortuosity proximal to or within the lesion\n\n          -  Angulation (\u2265 45o) proximal to or within the lesion\n\n          -  Calcification moderate or heavy\n\n          -  Previous intervention restenosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013349", 
            "org_study_id": "ELX-CL-1203"
        }, 
        "intervention": {
            "arm_group_label": "DESyne Novolimus Eluting CSS", 
            "intervention_name": "Subjects receiving the DESolve\u00ae Novolimus Eluting Bioresorbable Coronary Scaffold System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "gert.richardt@segebergerkliniken.de", 
                    "last_name": "Gert Richardt, Prof. Dr. med.", 
                    "phone": "+49 (4551) 802 4801"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Segeberg", 
                        "country": "Germany", 
                        "zip": "23795"
                    }, 
                    "name": "Herz-Kreislaufzentrum Bad Segeberg"
                }, 
                "investigator": {
                    "last_name": "Gert Richardt, Prof. Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "holger.nef@me.com", 
                    "last_name": "Holger Nef, Prof. Dr. med.", 
                    "phone": "+49 172 2052767"
                }, 
                "facility": {
                    "address": {
                        "city": "Giessen", 
                        "country": "Germany", 
                        "zip": "35392"
                    }, 
                    "name": "Universit\u00e4tsklinikum Giessen und Marburg GmbH"
                }, 
                "investigator": {
                    "last_name": "Holger Nef, Prof. Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dieter.fischer@ukmuenster.de", 
                    "last_name": "Dieter Fischer, Priv. Doz. Dr.", 
                    "phone": "+49 (0251) 834 5078"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "48149"
                    }, 
                    "name": "Universit\u00e4tsklinikum M\u00fcnster"
                }, 
                "investigator": {
                    "last_name": "Dieter Fischer, Priv. Doz. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trier", 
                        "country": "Germany", 
                        "zip": "54292"
                    }, 
                    "name": "Krankenhaus der Barmherzigen Br\u00fcder"
                }
            }, 
            {
                "contact": {
                    "email": "colombo.antonio@hsr.it", 
                    "last_name": "Antonio Colombo, MD", 
                    "phone": "+39 (02) 264 37 331"
                }, 
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20132"
                    }, 
                    "name": "Ospendale San Raffaele"
                }, 
                "investigator": {
                    "last_name": "Antonio Colombo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "POST-MARKET EVALUATION OF DESolve\u00ae NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization", 
                "measure": "Major Adverse Cardiac Events (MACE)", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013349"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Elixir Medical Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elixir Medical Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}